Branded

DEERFIELD, Ill. — In support of the more than 1.1 million people living with HIV in the United States, Walgreens on Monday announced its collaboration with the Centers for Disease Control and Prevention to develop and evaluate a model of HIV patient-centered care through a national project aimed at advancing clinical integration and medication therapy management. The program is another way Walgreens is extending its commitment to improve HIV prevention and treatment outcomes.

ROCKLAND, Mass. — A redesigned version of an injector pen used to treat infertility is available for distribution in the United States, the manufacturer said Monday.

EMD Serono, a subsidiary of German drug maker Merck KGaA, said that Gonal-f RFF Redi-ject, a disposable, pre-filled pen used for the drug Gonal-f RFF (follitropin alfa), had become available. The Food and Drug Administration approved the redesigned pen in October. Merck KGaA operates in the United States under the name EMD in order to avoid confusion with U.S.-based Merck & Co.

MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe's patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.

CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.

Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women's health markets. Financial terms of the deal were not disclosed.

NEW YORK — Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

Bloomberg News reported that ESI would pit companies like Gilead Sciences against others such as AbbVie when the new treatments become available in 2014 or 2015. The Food and Drug Administration announced last week the approval of Gilead's new drug, Sovaldi (sofosbuvir), which is designed to cut by three quarters the time needed for treatment.

ATLANTA — Flu vaccination prevented an estimated 6.6 million influenza-associated illnesses, 3.2 million medically attended illnesses, and 79,000 hospitalizations during the 2012-2013 flu season, according to a Centers for Disease Control and Prevention report in the Morbidity and Mortality Weekly Report published Thursday. CDC also reported today that despite the benefits of flu vaccination, only 40% of Americans 6 months and older had reported getting a flu vaccine this season as of early November 2013.

ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

NEW YORK — Diabetes organizations in several cities are getting a boost in funding from a Danish drug maker that specializes in developing treatments for the disease.

Novo Nordisk said it would provide funding to groups in Seattle; Portland, Ore.; and Rochester, Minn., as part of the Novo Nordisk Community Care initiative. The initiative provides funding to nonprofits that support educational programs for people with Type 2 diabetes.